Early Readout on Xaluritamig (Amg 509)

From here

amgen.com/newsroom/press-re...

“Interim results from a Phase 1 study of AMG 509 (xaluritamig) will be presented during a Proffered Paper Oral Session (Abstract #1765O), demonstrating that the novel bispecific STEAP1 x CD3 XmAb® 2+1 T-cell engager had a positive benefit/risk profile with robust anti-tumor activity in heavily pretreated patients with mCRPC (N=97). Overall, of the 67 RECIST-evaluable patients, 16 (24%) had confirmed partial responses (PR) and 32 (48%) had stable disease (SD), demonstrating encouraging preliminary efficacy. At higher dosing levels (n=37), 15 patients (41%) had confirmed PR and 14 (38%) with SD. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%; primarily low grade), fatigue (45%), myalgia (34%) and pyrexia (32%).

These results further justify exploration of this modality as a potential therapy for prostate cancer. Dose expansion and optimization are currently ongoing.”

There was a member here (Unknown58) that said he had a complete response but his profile and all his posts disappeared. Luckily the internet archive retained one of his posts.

web.archive.org/web/2022092...

His experience seemed at odds with the results mentioned in the press release. He had a complete response. The press release only mentions partial responses.

On tbe flip side, sadly one of our members (Philly13) had no luck with this trial. He was in a lower dose group. He later died.

Unknown58 had said he was not treated with chemo before entering the trial.

[Bethpage]

The archived post disappears in less than 5 seconds. Is there a trick to saving it that I don't know about? Thanks!

[Seasid in reply to Bethpage]

I had no problems with my Tor browser. Try it again.

[Hidden in reply to Bethpage]

i will post the whole thread here as text. It was a very hopeful thread.

[Bethpage in reply to Hidden]

Bless you!

[mypk]

The results of 67 evaluable patients now published are actually relatively old data collected until the end of May 2022 . I am in this study since July 2023 and I know that my data are not included. My data will probably be included in a follow-up publication in February 2024.

If I remember correctly, the first probands also received lower doses of AMG-509, starting at 10 mg to determine the maximum tolerated dose. Currently, probands are receiving 75 mg once a week.

So the 'news' are almost 1½ years old news.

[Bethpage]

I give up. I've tried over and over with Edge. This a.m., did the same with Chrome and with Foxfire. Now I've just tried Safari. Same results every time except that 5 seconds is being generous. Is there a membership? I can't tell because I just get a blank page with "Wayback Machine" in the top left corner. Interesting.

[j-o-h-n]

Quoting you:

Philly13 had no luck with this trial. He was in a lower dose group. He later died.

If this is true and I hope it's not and you have more info. please let me know the details. I will post them for all our members to view. Thank you......... (Philly 13 = nice guy)....

j-o-h-n Sunday 10/22/2023 11:27 PM DST

[mypk]

In my case, 22 weekly AMG-509 (Xaluritamig) infusions have so far resulted in "stable disease", which is exactly what that means. No regression and no progression of the disease. That is definitely better than progression of the disease.

👍

[mypk in reply to mypk]

Since July 2023 I have been a trial rabbit for AMG-509. Until March 2024 AMG 509 kept my bone metastases pretty stable. The scintigraphy images showed no progress. But then a CT-Scan showed that the cancer might have spread into my liver. A PSMA-PET-Scan confirmed that. That led to an immediate stop of AMG-509 infusions by the study sponsor. Next is a therapy with Lu-177-PSMA